in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment.
• Final dosing of the last patient concludes the Phase 3 study in people with Type 2 diabetes, event associated with a $10 million payment from Tonghua Dongbao to Adocia
• Phase 3 topline results are expected in H1 2025
• Granting of the Marketing Authorization will trigger an additional $20 million milestone payment, followed by double-digit royalties on sales